ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) Short Interest Update

ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) saw a large growth in short interest during the month of June. As of June 30th, there was short interest totaling 96,526 shares, a growth of 315.4% from the June 15th total of 23,236 shares. Approximately 3.3% of the shares of the company are short sold. Based on an average daily volume of 40,529 shares, the short-interest ratio is currently 2.4 days.

Institutional Investors Weigh In On ALPS Medical Breakthroughs ETF

A number of institutional investors have recently added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC bought a new position in ALPS Medical Breakthroughs ETF during the fourth quarter valued at about $26,000. Comerica Bank bought a new stake in shares of ALPS Medical Breakthroughs ETF in the 3rd quarter worth approximately $27,000. Harbor Investment Advisory LLC acquired a new stake in shares of ALPS Medical Breakthroughs ETF during the 2nd quarter worth approximately $29,000. Global Retirement Partners LLC acquired a new stake in shares of ALPS Medical Breakthroughs ETF during the 4th quarter worth approximately $34,000. Finally, Raymond James Financial Inc. bought a new stake in shares of ALPS Medical Breakthroughs ETF during the second quarter valued at approximately $82,000.

ALPS Medical Breakthroughs ETF Stock Performance

Shares of NYSEARCA:SBIO traded down $1.89 on Monday, hitting $65.33. 76,019 shares of the company were exchanged, compared to its average volume of 37,618. The company’s 50 day moving average price is $56.84 and its two-hundred day moving average price is $53.61. ALPS Medical Breakthroughs ETF has a one year low of $32.21 and a one year high of $69.34.

ALPS Medical Breakthroughs ETF Company Profile

The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.